(OTCBB:BZYR) Burzynski Research Institute, Inc.

Turning Pennies into dollars: (OTCBB:BZYR) Burzynski Research Institute, Inc.

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/bzyr

Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers

(OTCBB:BZYR) Burzynski Research Institute, Inc.

Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers

Thursday February 5, 9:19 am ET

Cases Show Promise of Personalized Treatment in Achieving Complete Response in Patients with Hepatocellular Carcinoma and Adenocarcinoma of the Pancreas

HOUSTON-Medical doctors from the Burzynski Research Institute, Inc. and the Burzynski Clinic in Houston, Texas will present case studies of patients with advanced liver and pancreatic cancers who were treated with combination gene-targeted therapies. These initial findings will be discussed at the 2009 International Congress on Anti-Cancer Treatment at the Palais des Congres in Paris, France from February 3rd-6th. The Congress is an international educational and scientific meeting that gathers together the world?s foremost scientists and oncology experts to provide comprehensive updates in the management of cancer.

Barbara Burzynski, M.D., Robert Weaver, M.D., Eva Kubove, M.D., and Stanislaw R. Burzynski, M.D., Ph.D., will represent BRI and BC, presenting two reports of early results of combination gene-targeted agents in a specific group of patients treated at BC.

Pancreatic cancer continues to create very difficult therapeutic problems for clinicians. Standard chemotherapy has shown to be limited in managing the disease for the longer-term. The report being presented summarizes the initial effects of combination gene-targeted therapies to treat eleven patients with advanced pancreatic cancer, including a case study on a patient in complete response seven months after the diagnosis of his disease.

Hepatocellular carcinoma is a primary liver cancer that carries nearly 100% mortality and has shown to be highly resistant to conventional therapies. The discussion undertaken at the Congress looks at preliminary findings across a group of seven patients undergoing personalized treatment of their disease. Case reports highlighted involve two patients diagnosed with hepatocellular carcinoma who failed standard therapy; one of them relapsing post liver transplant. Both patients have achieved complete response.

?These cases require longer follow-up and confirmation in a larger patient population. However, the early results are quite compelling when you consider the deadly outcome of these advanced liver and pancreatic cancers,? said Stanislaw R. Burzynski, M.D., Ph.D.

Burzynski Research Institute, Inc. is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and Phase III clinical trials.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Burzynski Research Institute, Inc. cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for antineoplastons A10 and AS2-1, risks associated with BRI?s ability to raise sufficient capital from the development of its technology towards commercialization, and other risks described in BRI?s periodic reports filed with the Securities and Exchange Commission. BRI does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein.

Contact:

For Burzynski Research Institute, Inc. Darlene Hodge, 713-335-5636 Darlene@burzynskiclinic.com or Carolyn Powers, 713-335-5664 Carolyn@burzynskiclinic.com or Amanda Cheslock, 212-446-1884 acheslock@sloanepr.com Source: Burzynski Research Institute, Inc.

Profile for Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. engages in the research, production, marketing, promotion, and sale of medical chemical compounds. Its medical compounds include growth-inhibiting peptides, amino acid derivatives, and organic acids, which are known under the trade name Antineoplastons used in the treatment of human cancer. The company is conducting a range of Phase II clinical studies for the treatment of various cancers using a combination of Antineoplastons A10 and AS2-1. Its clinical trials study the use of Antineoplastons A10 and AS2-1 for treating patients with glioblastoma multiforme, anaplastic astrocytoma, brain tumors, brain stem glioma, primitive neuroectodermal tumors, low grade...

LAST $0.06 USD



Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com